Page 1,389«..1020..1,3881,3891,3901,391..1,4001,410..»

Bone Marrow & Stem Cell Transplant | Weill Cornell Medicine

Posted: March 8, 2019 at 6:43 am

Bone Marrow & Stem Cell Transplant

The Bone Marrow and Stem Cell Transplant Program at Weill Cornell Medicine was established with the mission of providing the best care and most innovative research in a compassionate and comfortable environment.

We take a multidisciplinary approach to care for patients with cancer and blood diseases who need stem cell transplants, providing world-class clinical care in collaboration with experts in leukemia, lymphoma, myeloma and other blood disorders. Based at NewYork-Presbyterian/Weill Cornell Medical Center, one of the top ten general hospitals in the nation, the expertise of our consulting team is unsurpassed.

Our patients and families cope with life-threatening illness; as such, sensitivity and compassion are a priority for our team. We view each patient as an individual, and our approach ensures that each treatment regimen is narrowly tailored to meet the unique, changing needs of our patients and their families before, during and after transplant.

As New Yorks premier healthcare institution, Weill Cornell Medicine is at the forefront of scientific research and clinical trials, enabling us to provide a full range of diagnostic and treatment protocols, including the latest breakthroughs in medicine.

Our Team

Our team of internationally-recognized bone marrow transplant and stem cell surgery specialists is known for advanced work and published research in:

Treating patients with aggressive leukemia and myelodysplastic syndromes

Bridge protocols for patients with refractory lymphoma and leukemia

Novel strategies to mobilize stem cells and improve transplantation for patients with multiple myeloma, leukemia and lymphoma

Transplants for solid tumors, severe auto-immune disorders, and AIDS

Treatment

We pride ourselves on exceptional outcomes and offer patients the most advanced diagnostic methods and treatment therapies to improve quality of life, including:

Umbilical cord blood transplant

Outpatient transplant

Autologous stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of the patients own blood

Allogeneic stem cell transplant; uses stem cells extracted from the bone marrow or peripheral blood of a matching donor

Hematopoietic stem cell transplant; used to treat certain cancers of the blood/bone marrow, including leukemia and myeloma

Matched unrelated donor stem cell transplantation through the National Donor Matching Program

Non-ablative "mini" transplants

Haplo-Cord Transplant, allowing us to find donors for all patients, regardless of age or ethnic background

Bendamustine, a therapy that is well-tolerated and has excellent response rates in patients with myeloma

Novel forms of transplant, offering hope and success to older patients with leukemia

Clinical Trials

Clinical trials are important to improve outcomes and offer new treatment options. At Weill Cornell Medicine, we conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials. As active members of the international cancer research community, our oncologists also collaborate with other research centers to offer patients the most promising treatments available.

Second Opinions

In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.

Why Choose Us?

Our collaborative approach means our patients receive supportive, comprehensive care and the most cutting-edge stem cell therapy and treatments. This enables patients to receive the best possible transplant outcomes. Additionally, we offer more allogeneic stem cell transplants for older adults than any other center in New York City and the entire tri-state area.

For more information or to schedule an appointment, call us at 212-746-2119 or 212-746-2646.

Located in New York City, Weill Cornell Medical College is ranked among the nations best by U.S. News & World Report year after year.

Read more from the original source:
Bone Marrow & Stem Cell Transplant | Weill Cornell Medicine

Posted in Cell Medicine | Comments Off on Bone Marrow & Stem Cell Transplant | Weill Cornell Medicine

OMIM Entry – * 104311 – PRESENILIN 1; PSEN1

Posted: March 8, 2019 at 6:43 am

Alzheimer's Disease Collaborative Group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genet. 11: 219-222, 1995. [PubMed: 7550356] [Full Text: https://dx.doi.org/10.1038/ng1095-219%5D

Ataka, S., Tomiyama, T., Takuma, H., Yamashita, T., Shimada, H., Tsutada, T., Kawabata, K., Mori, H., Miki, T. A novel presenilin-1 mutation (leu85pro) in early-onset Alzheimer disease with spastic paraparesis. Arch. Neurol. 61: 1773-1776, 2004. [PubMed: 15534188] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneur.61.11.1773%5D

Athan, E. S., Williamson, J., Ciappa, A., Santana, V., Romas, S. N., Lee, J. H., Rondon, H., Lantigua, R. A., Medrano, M., Torres, M., Arawaka, S., Rogaeva, E., and 10 others. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 286: 2257-2263, 2001. [PubMed: 11710891] [Full Text: https://jamanetwork.com/journals/jama/fullarticle/vol/286/pg/2257%5D

Bai, G., Chivatakarn, O., Bonanomi, D., Lettieri, K., Franco, L., Xia, C., Stein, E., Ma, L., Lewcock, J. W., Pfaff, S. L. Presenilin-dependent receptor processing is required for axon guidance. Cell 144: 106-118, 2011. [PubMed: 21215373] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(10)01375-9%5D

Bai, X., Yan, C., Yang, G., Lu, P., Ma, D., Sun, L., Zhou, R., Scheres, S. H. W., Shi, Y. An atomic structure of human gamma-secretase. Nature 525: 212-217, 2015. [PubMed: 26280335] [Full Text: https://doi.org/10.1038/nature14892%5D

Beck, J. A., Poulter, M., Campbell, T. A., Uphill, J. B., Adamson, G., Geddes, J. F., Revesz, T., Davis, M. B., Wood, N. W., Collinge, J., Tabrizi, S. J. Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Hum. Molec. Genet. 13: 1219-1224, 2004. [PubMed: 15115757] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddh134%5D

Beglopoulos, V., Sun, X., Saura, C. A., Lemere, C. A., Kim, R. D., Shen, J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J. Biol. Chem. 279: 46907-46914, 2004. [PubMed: 15345711] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=15345711%5D

Bertoli Avella, A. M., Teruel, B. M., Llibre Rodriguez, J. J., Gomez Viera, N., Borrajero Martinez, I., Severijnen, E. A., Joosse, M., van Duijn, C. M., Heredero Baute, L., Heutink, P. A novel presenilin 1 mutation (L174M) in a large Cuban family with early onset Alzheimer disease. Neurogenetics 4: 97-104, 2002. [PubMed: 12484344]

Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G, Sisodia, S. S. Familial Alzheimer's disease-linked presenilin 1 variants elevate A-beta-1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013, 1996. [PubMed: 8938131] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(00)80230-5%5D

Bruni, A. C., Bernardi, L., Colao, R., Rubino, E., Smirne, N., Frangipane, F., Terni, B., Curcio, S. A. M., Mirabelli, M., Clodomiro, A., Di Lorenzo, R., Maletta, R., and 23 others. Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology 74: 798-806, 2010. [PubMed: 20164095] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=20164095%5D

Buckler, A. J., Chang, D. D., Graw, S. L., Brook, J. D., Haber, D. A., Sharp, P. A., Housman, D. E. Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc. Nat. Acad. Sci. 88: 4005-4009, 1991. [PubMed: 1850845] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=1850845%5D

Cai, D., Netzer, W. J., Zhong, M., Lin, Y., Du, G., Frohman, M., Foster, D. A., Sisodia, S. S., Xu, H., Gorelick, F. S., Greengard, P. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc. Nat. Acad. Sci. 103: 1941-1946, 2006. [PubMed: 16449386] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16449386%5D

Cai, D., Zhong, M., Wang, R., Netzer, W. J., Shields, D., Zheng, H., Sisodia, S. S., Foster, D. A., Gorelick, F. S., Xu, H., Greengard, P. Phospholipase D1 corrects impaired beta-APP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc. Nat. Acad. Sci. 103: 1936-1940, 2006. [PubMed: 16449385] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16449385%5D

Chau, D.-M., Crump, C. J., Villa, J. C., Scheinberg, D. A., Li, Y.-M. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of gamma-secretase. J. Biol. Chem. 287: 17288-17296, 2012. [PubMed: 22461631] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=22461631%5D

Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim. S., Schenk, D., Fraser, P., St George Hyslop, P., Selkoe, D. J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med. 3: 67-72, 1997. [PubMed: 8986743]

Clark, R. F., Hutton, M., Talbot, C., Wragg, M., Lendon, C., Busfield, F., Han, S. W., Perez-Tur, J., Adams, M., Fuldner, R., Roberts, G., Karran, E., Hardy, J., Goate, A. The role of presenilin 1 in the genetics of Alzheimer's disease. Cold Spring Harbor Symp. Quant. Biol. 61: 551-558, 1996. [PubMed: 9246481] [Full Text: http://symposium.cshlp.org/cgi/pmidlookup?view=long&pmid=9246481%5D

Crook, R., Verkkoniemi, A., Perez-Tur, J., Mehta N., Baker, M., Houlden, H., Farrer, M., Hutton, M., Lincoln, S., Hardy, J., Gwinn, K., Somer, M., Paetau, A., Kalimo, H., Ylikoski, R., Poyhonen, M., Kucera, S., Haltia, M. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nature Med. 4: 452-455, 1998. [PubMed: 9546792]

Cruts, M., Van Broeckhoven, C. Presenilin mutations in Alzheimer's disease. Hum. Mutat. 11: 183-190, 1998. [PubMed: 9521418] [Full Text: https://doi.org/10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.0.CO;2-J]

Cruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., St George-Hyslop, P. H., Hofman, A., Van Broeckhoven, C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum. Molec. Genet. 7: 43-51, 1998. [PubMed: 9384602]

Davis, J. A., Naruse, S., Chen, H., Eckman, C., Younkin, S., Price, D. L., Borchelt, D. R., Sisodia, S. S., Wong, P. C. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron 20: 603-609, 1998. [PubMed: 9539132] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(00)80998-8%5D

De Jonghe, C., Cruts, M., Rogaeva, E. A., Tysoe, C., Singleton, A., Vanderstichele, H., Meschino, W., Dermaut, B., Vanderhoeven, I., Backhovens, H., Vanmechelen, E., Morris, C. M., Hardy, J., Rubinsztein, D. C., St George-Hyslop, P. H., Van Broeckhoven, C. Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased A-beta-42 secretion. Hum. Molec. Genet. 8: 1529-1540, 1999. [PubMed: 10401002]

De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., Kopan, R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398: 518-522, 1999. [PubMed: 10206645] [Full Text: https://doi.org/10.1038/19083%5D

De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., Van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 387-390, 1998. [PubMed: 9450754] [Full Text: https://doi.org/10.1038/34910%5D

De Strooper, B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38: 9-12, 2003. [PubMed: 12691659] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896627303002058%5D

Dermaut, B., Cruts, M., Slooter, A. J. C., Van Gestel, S., De Jonghe, C., Vanderstichele, H., Vanmechelen, E., Breteler, M. M., Hofman, A., van Duijn, C. M., Van Broeckhoven, C. The glu318-to-gly substitution in presenilin 1 is not causally related to Alzheimer disease. (Letter) Am. J. Hum. Genet. 64: 290-292, 1999. [PubMed: 9915968] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0002-9297(07)61682-6%5D

Dermaut, B., Kumar-Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., Pickut, B. A., Peeters, K., van den Broeck, M., Vennekens, K., Claes, S., Cruts, M., Cras, P., Martin, J.-J., Van Broeckhoven, C., De Deyn, P. P. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann. Neurol. 55: 617-626, 2004. [PubMed: 15122701] [Full Text: https://doi.org/10.1002/ana.20083%5D

Devi, G., Fotiou, A., Jyrinji, D., Tycko, B., DeArmand, S., Rogaeva, E., Song, Y.-Q., Medieros, H., Liang, Y., Orlacchio, A., Williamson, J., St George-Hyslop, P., Mayeux, R. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch. Neurol. 57: 1454-1457, 2000. [PubMed: 11030797] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/vol/57/pg/1454%5D

Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., Zheng, H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha-7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277: 22768-22780, 2002. [PubMed: 11912199] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=11912199%5D

Dolzhanskaya, N., Gonzalez, M. A., Sperziani, F., Stefl, S., Messing, J., Wen, G. Y., Alexov, E., Zuchner, S., Velinov, M. A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease. J. Alzheimers Dis. 39: 23-27, 2014. [PubMed: 24121961] [Full Text: https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-131340%5D

Donoviel, D. B., Hadjantonakis, A.-K., Ikeda, M., Zheng, H., St George Hyslop, P., Bernstein, A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 13: 2801-2810, 1999. [PubMed: 10557208] [Full Text: http://www.genesdev.org/cgi/pmidlookup?view=long&pmid=10557208%5D

Duff, K., Eckman, C., Zehr, C., Yu, X, Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., Youndkin, S. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713, 1996. [PubMed: 8878479] [Full Text: https://doi.org/10.1038/383710a0%5D

Esselens, C., Oorschot, V., Baert, V., Raemaekers, T., Spittaels, K., Serneels, L., Zheng, H., Saftig, P., De Strooper, B., Klumperman, J., Annaert, W. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J. Cell Biol. 166: 1041-1054, 2004. [PubMed: 15452145] [Full Text: http://jcb.rupress.org/cgi/pmidlookup?view=long&pmid=15452145%5D

Feng, R., Rampon, C., Tang, Y.-P., Shrom, D., Jin, J., Kyin, M., Sopher, B., Miller, M. W., Ware, C. B., Martin, G. M., Kim, S. H., Langdon, R. B., Sisodia, S. S., Tsien, J. Z. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32: 911-926, 2001. Note: Erratum: Neuron 33: 313 only, 2002. [PubMed: 11738035] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(01)00523-2%5D

Fox, N. C., Kennedy, A. M., Harvey, R. J., Lantos, P. L., Roques, P. K., Collinge, J., Hardy, J., Hutton, M., Stevens, J. M., Warrington, E. K., Rossor, M. N. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene: pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 120: 491-501, 1997. [PubMed: 9126060]

Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Hai, B., Ellis, M. C., Parks, A. L., Xu, W., Li, J., Gurney, M., Myers, R. L., Himes, C. S., Hiebsch, R., Ruble, C., Nye, J. S., Curtis, D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of beta-APP, and presenilin protein accumulation. Dev. Cell 3: 85-97, 2002. [PubMed: 12110170] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S1534-5807(02)00189-2%5D

Ganguly, A., Feldman, R. M. R., Guo, M. Ubiquilin antagonizes presenilin and promotes neurodegeneration in Drosophila. Hum. Molec. Genet. 17: 293-302, 2008. [PubMed: 17947293] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddm305%5D

Georgakopoulos, A., Marambaud, P., Efthimiopoulos, S., Shioi, J., Cui, W., Li, H.-C., Schutte, M., Gordon, R., Holstein, G. R., Martinelli, G., Mehta, P., Friedrich, V. L., Jr., Robakis, N. K. Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Molec. Cell 4: 893-902, 1999. [PubMed: 10635315] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S1097-2765(00)80219-1%5D

Godbolt, A. K., Beck, J. A., Collinge, J., Garrard, P., Warren, J. D., Fox, N. C., Rossor, M. N. A presenilin 1 R278I mutation presenting with language impairment. Neurology 63: 1702-1704, 2004. [PubMed: 15534260] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15534260%5D

Goldman, J. S., Johnson, J. K., McElligott, K., Suchowersky, O., Miller, B. L., Van Deerlin, V. M. Presenilin 1 Glu318Gly polymorphism: interpret with caution. Arch. Neurol. 62: 1624-1627, 2005. [PubMed: 16216949] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneur.62.10.1624%5D

Grilli, M., Diodato, E., Lozza, G., Brusa, R., Casarini, M., Uberti, D., Rozmahel, R., Westaway, D., St George-Hyslop, P., Memo, M., Ongini, E. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc. Nat. Acad. Sci. 97: 12822-12827, 2000. [PubMed: 11070093] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11070093%5D

Guo, M., Hong, E. J., Fernandes, J., Zipursky, S. L., Hay, B. A. A reporter for amyloid precursor protein gamma-secretase activity in Drosophila. Hum. Molec. Genet. 12: 2669-2678, 2003. [PubMed: 12944419] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddg292%5D

Gustafson, L., Brun, A., Englund, E., Hagnell, O., Nilsson, K., Stensmyr, M., Ohlin, A.-K., Abrahamson, M. A 50-year perspective of a family with chromosome-14-linked Alzheimer's disease. Hum. Genet. 102: 253-257, 1998. [PubMed: 9544835]

Halliday, G. M., Song, Y. J. C., Lepar, G., Brooks, W. S., Kwok, J. B., Kersaitis, C., Gregory, G., Shepherd, C. E., Rahimi, F., Schofield, P. R., Kril, J. J. Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann. Neurol. 57: 139-143, 2005. [PubMed: 15622541] [Full Text: https://doi.org/10.1002/ana.20366%5D

Handler, M., Yang, X., Shen, J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development 127: 2593-2606, 2000. [PubMed: 10821758] [Full Text: http://dev.biologists.org/cgi/pmidlookup?view=long&pmid=10821758%5D

Hartmann, D. From Alzheimer's disease to skin tumors: the catenin connection. Proc. Nat. Acad. Sci. 98: 10522-10523, 2001. [PubMed: 11553799] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11553799%5D

Harvey, R. J., Ellison, D., Hardy, J., Hutton, M., Roques, P. K., Collinge, J., Fox, N. C., Rossor, M. N. Chromosome 14 familial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucine-to-serine (L250S) substitution at codon 250 of the presenilin 1 gene. J. Neurol. Neurosurg. Psychiat. 64: 44-49, 1998. [PubMed: 9436726] [Full Text: http://jnnp.bmj.com/cgi/pmidlookup?view=long&pmid=9436726%5D

Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., Golenbock, D. T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-678, 2013. [PubMed: 23254930] [Full Text: https://doi.org/10.1038/nature11729%5D

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 274: 99-103, 1996. [PubMed: 8810256] [Full Text: http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=8810256%5D

Hull, M., Fiebich, B. L., Dykierek, P., Schmidtke, K., Nitzsche, E., Orszagh, M., Deuschl, G., Moser, E., Schumacher, M., Lucking, C., Berger, M., Bauer, J. Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: a 7-year follow-up of a patient with a mutation at codon 139. Europ. Arch. Psychiat. Clin. Neurosci. 248: 123-129, 1998. [PubMed: 9728730]

Ikeuchi, T., Sisodia, S. S. The notch ligands, delta-1 and jagged-2, are substrates for presenilin-dependent 'gamma-secretase' cleavage. J. Biol. Chem. 278: 7751-7754, 2003. [PubMed: 12551931] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12551931%5D

Ishikawa, A., Piao, Y.-S., Miyashita, A., Kuwano, R., Onodera, O., Ohtake, H., Suzuki, M., Nishizawa, M., Takahashi, H. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann. Neurol. 57: 429-434, 2005. [PubMed: 15732120] [Full Text: https://doi.org/10.1002/ana.20393%5D

Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., Younkin, S. G., Borchelt, D. R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Molec. Genet. 13: 159-170, 2004. [PubMed: 14645205] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddh019%5D

Jarrett, J. T., Berger, E. P., Lansbury, P. T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697, 1993. [PubMed: 8490014]

Johnson, K. A., Lopera, F., Jones, K., Becker, A., Sperling, R., Hilson, J., Londono, J., Siegert, I., Arcos, M., Moreno, S., Madrigal, L., Ossa, J., Pineda, N., Ardila, A., Roselli, M., Albert, M. S., Kosik, K. S., Rios, A. Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 56: 1545-1551, 2001. [PubMed: 11402113] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=11402113%5D

Jorgensen, P., Bus, C., Pallisgaard, N., Bryder, M., Jorgensen, A. L. Familial Alzheimer's disease co-segregates with a met146ile substitution in presenilin-1. Clin. Genet. 50: 281-286, 1996. [PubMed: 9007311] [Full Text: https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0009-9163&date=1996&volume=50&issue=5&spage=281%5D

Kaether, C., Capell, A., Edbauer, D., Winkler, E., Novak, B., Steiner, H., Haass, C. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity. EMBO J. 23: 4738-4748, 2004. [PubMed: 15549135] [Full Text: http://emboj.embopress.org/cgi/pmidlookup?view=long&pmid=15549135%5D

Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., Goldstein, L. S. B. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643-648, 2001. [PubMed: 11740561] [Full Text: https://doi.org/10.1038/414643a%5D

Kamal, A., Stokin, G. B., Yang, Z., Xia, C., Goldstein, L. S. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28: 449-459, 2000. [PubMed: 11144355] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(00)00124-0%5D

Kang, D. E., Soriano, S., Xia, X., Eberhart, C. G., De Strooper, B., Zheng, H., Koo, E. H. Presenilin couples the paired phosphorylation of beta-catenin independent of Axin: implications for beta-catenin activation in tumorigenesis. Cell 110: 751-762, 2002. [PubMed: 12297048] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092867402009704%5D

Katayama, T., Imaizumi, K., Honda, A., Yoneda, T., Kudo, T., Takeda, M., Mori, K., Rozmahel, R., Fraser, P., St. George-Hyslop, P., Tohyama, M. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J. Biol. Chem. 276: 43446-43454, 2001. [PubMed: 11551913] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=11551913%5D

Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., Goate, A. M. Extreme cerebrospinal fluid amyloid-beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann. Neurol. 61: 446-453, 2007. [PubMed: 17366635] [Full Text: https://doi.org/10.1002/ana.21099%5D

Kopan, R., Goate, A. A common enzyme connects Notch signaling and Alzheimer's disease. Genes Dev. 14: 2799-2806, 2000. [PubMed: 11090127] [Full Text: http://www.genesdev.org/cgi/pmidlookup?view=long&pmid=11090127%5D

Kosik, K. S., Munoz, C., Lopez, L., Arcila, M. L., Garcia, G., Madrigal, L., Moreno, S., Rios Romenets, S., Lopez, H., Gutierrez, M., Langbaum, J. B., Cho, W., Suliman, S., Tariot, P., Ho, C., Reiman, E. M., Lopera, F. Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation. Neurology 84: 206-208, 2015. [PubMed: 25471389] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=25471389%5D

Kounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., Yu, C., Pleynet, D., and 9 others. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67: 769-780, 2010. [PubMed: 20826309] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(10)00628-8%5D

Kovacs, D. M., Fausett, H. J., Page, K. J., Kim, T.-W., Moir, R. D., Merriam, D. E., Hollister, R. D., Hallmark, O. G., Mancini, R., Felsenstein, K. M., Hyman, B. T., Tanzi, R. E., Wasco, W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Med. 2: 224-229, 1996. [PubMed: 8574969]

Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., Van Broeckhoven, C. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A-beta-42 and decreased A-beta-40. Hum. Mutat. 27: 686-695, 2006. [PubMed: 16752394] [Full Text: https://doi.org/10.1002/humu.20336%5D

Kwok, J. B. J., Halliday, G. M., Brooks, W. S., Dolios, G., Laudon, H., Murayama, O., Hallupp, M., Badenhop, R. F., Vickers, J., Wang, R., Naslund, J., Takashima, A., Gandy, S. E., Schofield, P. R. Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J. Biol. Chem. 278: 6748-6754, 2003. [PubMed: 12493737] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12493737%5D

Kwok, J. B. J., Taddei, K., Hallupp, M., Fisher, C., Brooks, W. S., Broe, G. A., Hardy, J., Fulham, M. J., Nicholson, G. A., Stell, R., St. George Hyslop, P. H., Fraser, P. E., and 6 others. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport 8: 1537-1542, 1997. [PubMed: 9172170] [Full Text: http://Insights.ovid.com/pubmed?pmid=9172170%5D

Lambert, J.-C., Mann, D. M. A., Harris, J. M., Chartier-Harlin, M.-C., Cumming, A., Coates, J., Lemmon, H., StClair, D., Iwatsubo, T., Lendon, C. The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased A-beta load in brain. J. Med. Genet. 38: 353-355, 2001. [PubMed: 11389157] [Full Text: http://jmg.bmj.com/cgi/pmidlookup?view=long&pmid=11389157%5D

Landman, N., Jeong, S. Y., Shin, S. Y., Voronov, S. V., Serban, G., Kang, M. S., Park, M. K., Di Paolo, G., Chung, S., Kim, T.-W. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Nat. Acad. Sci. 103: 19524-19529, 2006. [PubMed: 17158800] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=17158800%5D

Laudon, H., Hansson, E. M., Melen, K., Bergman, A., Farmery, M. R., Winblad, B., Lendahl, U., von Heijne, G., Naslund, J. A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 280: 35352-35360, 2005. [PubMed: 16046406] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=16046406%5D

Lazarov, O., Robinson, J., Tang, Y.-P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M.-Y., Hersh, L. B., Sapolsky, R. M., Mirnics, K., Sisodia, S. S. Environmental enrichment reduces A-beta levels and amyloid deposition in transgenic mice. Cell 120: 701-713, 2005. [PubMed: 15766532] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(05)00089-9%5D

Lee, S.-F., Shah, S., Li, H., Yu, C., Han, W., Yu, G. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J. Biol. Chem. 277: 45013-45019, 2002. [PubMed: 12297508] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12297508%5D

Leissring, M. A., Akbari, Y., Fanger, C. M., Cahalin, M. D., Mattson, M. P., LaFerla, F. M. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149: 793-797, 2000. [PubMed: 10811821] [Full Text: http://jcb.rupress.org/cgi/pmidlookup?view=long&pmid=10811821%5D

Lemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., Hincapie, L., Arango, J. C., Anthony, D. C., Koo, E. H., Goate, A. M., Selkoe, D. J., Arango, J. C. The E280A presenilin 1 Alzheimer mutation produces increased A-beta-42 deposition and severe cerebellar pathology. Nature Med. 2: 1146-1150, 1996. [PubMed: 8837617]

Lewis, P. A., Perez-Tur, J., Golde, T. E., Hardy, J. The presenilin 1 C92S mutation increases A-beta-42 production. Biochem. Biophys. Res. Commun. 277: 261-263, 2000. [PubMed: 11027672] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(00)93646-5%5D

Li, D., Parks, S. B., Kushner, J. D., Nauman, D., Burgess, D., Ludwigsen, S., Partain, J., Nixon, R. R., Allen, C. N., Irwin, R. P., Jakobs, P. M., Litt, M., Hershberger, R. E. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 79: 1030-1039, 2006. [PubMed: 17186461] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0002-9297(07)63465-X%5D

Li, J., Xu, M., Zhou, H., Ma, J., Potter, H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90: 917-927, 1997. [PubMed: 9298903] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(00)80356-6%5D

Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X.-P., Yin, K.-C., Shafer, J. A., Gardell, S. J. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405: 689-694, 2000. [PubMed: 10864326] [Full Text: https://doi.org/10.1038/35015085%5D

Lleo, A., Berezovska, O., Herl, L., Raju, S., Deng, A., Bacskai, B. J., Frosch, M. P., Irizarry, M., Hyman, B. T. Nonsteroidal anti-inflammatory drugs lower A-beta-42 and change presenilin 1 conformation. Nature Med. 10: 1065-1066, 2004. [PubMed: 15448688] [Full Text: https://dx.doi.org/10.1038/nm1112%5D

Lopera, F., Ardilla, A., Martinez, A., Madrigal, L., Arango-Viana, J. C., Lemere, C. A., Arango-Lasprilla, J. C., Hincapie, L., Arcos-Burgos, M., Ossa, J. E., Behrens, I. M., Norton, J., Lendon, C., Goate, A. M., Ruiz-Linares, A., Rosselli, M., Kosik, K. S. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277: 793-799, 1997. [PubMed: 9052708] [Full Text: https://jamanetwork.com/journals/jama/fullarticle/vol/277/pg/793%5D

Lu, P., Bai, X., Ma, D., Xie, T., Yan, C., Sun, L., Yang, G., Zhao, Y., Zhou, R., Scheres, S. H. W., Shi, Y. Three-dimensional structure of human gamma-secretase. Nature 512: 166-170, 2014. [PubMed: 25043039] [Full Text: https://doi.org/10.1038/nature13567%5D

Marambaud, P., Wen, P. H., Dutt, A., Shioi, J., Takeshima, A., Siman, R., Robakis, N. K. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114: 635-645, 2003. [PubMed: 13678586] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092867403006512%5D

Matsubara-Tsutsui, M., Yasuda, M., Yamagata, H., Nomura, T., Taguchi, K., Kohara, K., Miyoshi, K., Miki, T. Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am. J. Med. Genet. 114: 292-298, 2002. [PubMed: 11920851] [Full Text: https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0148-7299&date=2002&volume=114&issue=3&spage=292%5D

Mercken, M., Takahashi, H., Honda, T., Sato, K., Murayama, M., Nakazato, Y., Noguchi, K., Imahori, K., Takashima, A. Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: evidence that Alzheimer mutations affect proteolytic processing. FEBS Lett. 389: 297-303, 1996. [PubMed: 8766720] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/0014-5793(96)00608-4%5D

Moehlmann, T., Winkler, E., Xia, X., Edbauer, D., Murrell, J., Capell, A., Kaether, C., Zheng, H., Ghetti, B., Haass, C., Steiner, H. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A-beta(42) production. Proc. Nat. Acad. Sci. 99: 8025-8030, 2002. [PubMed: 12048239] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=12048239%5D

Moonis, M., Swearer, J. M., Dayaw, M. P. E., St. George-Hyslop, P., Rogaeva, E., Kawarai, T., Pollen, D. A. Familial Alzheimer disease: decreases in CSF amyloid-beta-42 levels precede cognitive decline. Neurology 65: 323-325, 2005. [PubMed: 16043812] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=16043812%5D

Morelli, L., Prat, M. I., Levy, E., Mangone, C. A., Castano, E. M. Presenilin 1 met146leu variant due to an A-T transversion in an early-onset familial Alzheimer's disease pedigree from Argentina. Clin. Genet. 53: 469-473, 1998. [PubMed: 9712537] [Full Text: https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0009-9163&date=1998&volume=53&issue=6&spage=469%5D

Moretti, P., Lieberman, A. P., Wilde, E. A., Giordani, B. I., Kluin, K. J., Koeppe, R. A., Minoshima, S., Kuhl, D. E., Seltzer, W. K., Foster, N. L. Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis. Neurology 62: 1865-1868, 2004. [PubMed: 15159497] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15159497%5D

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., Arendash, G. W. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985, 2000. Note: Erratum Nature 412: 660 only, 2001. [PubMed: 11140686] [Full Text: https://doi.org/10.1038/35050116%5D

Murrell, J., Ghetti, B., Cochran, E., Macias-Islas, M. A., Medina, L., Varpetian, A., Cummings, J. L., Mendez, M. F., Kawas, C., Chui, H., Ringman, J. M. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco state, Mexico: an additional fifteen families. (Letter) Neurogenetics 7: 277-279, 2006. [PubMed: 16897084] [Full Text: https://dx.doi.org/10.1007/s10048-006-0053-1%5D

Ni, C.-Y., Murphy, M. P., Golde, T. E., Carpenter, G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181, 2001. [PubMed: 11679632] [Full Text: http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=11679632%5D

Nielsen, A. L., Holm, I. E., Johansen, M., Bonven, B., Jorgensen, P., Jorgensen, A. L. A new splice variant of glial fibrillary acidic protein, GFAP-epsilon, interacts with the presenilin proteins. J. Biol. Chem. 277: 29983-29991, 2002. [PubMed: 12058025] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12058025%5D

Nornes, S., Newman, M., Verdile, G., Wells, S., Stoick-Cooper, C. L., Tucker, B., Frederich-Sleptsova, I., Martins, R., Lardelli, M. Interference with splicing of presenilin transcripts has potent dominant negative effects on presenilin activity. Hum. Molec. Genet. 17: 402-412, 2008. [PubMed: 17981814] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddm317%5D

Norton, J. B., Cairns, N. J., Chakraverty, S., Wang, J., Levitch, D., Galvin, J. E., Goate, A. Presenilin-1 G217R mutation linked to Alzheimer disease with cotton wool plaques. Neurology 73: 480-482, 2009. [PubMed: 19667325] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=19667325%5D

O'Riordan, S., McMonagle, P., Janssen, J. C., Fox, N. C., Farrell, M., Collinge, J., Rossor, M. N., Hutchinson, M. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 59: 1108-1110, 2002. [PubMed: 12370477] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12370477%5D

Page, K., Hollister, R., Tanzi, R. E., Hyman, B. T. In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Proc. Nat. Acad. Sci. 93: 14020-14024, 1996. [PubMed: 8943053] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=8943053%5D

Parimoo, S., Patanjali, S. R., Shukla, H., Chaplin, D. D., Weissman, S. M. cDNA selection: efficient PCR approach for the selection of cDNAs encoded in large chromosomal DNA fragments. Proc. Nat. Acad. Sci. 88: 9623-9627, 1991. [PubMed: 1946377] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=1946377%5D

Pasternak, S. H., Bagshaw, R. D., Guiral, M., Zhang, S., Ackerley, C. A., Pak, B. J., Callahan, J. W., Mahuran, D. J. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J. Biol. Chem. 278: 26687-26694, 2003. [PubMed: 12736250] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12736250%5D

Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., Garcia, G., Tirado, V., Norton, J., Rios, S., Martinez, M., Kosik, K. S., Lopera, F., Goate, A. M. Apolipoprotein E-epsilon-4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann. Neurol. 54: 163-169, 2003. [PubMed: 12891668] [Full Text: https://doi.org/10.1002/ana.10636%5D

The rest is here:
OMIM Entry - * 104311 - PRESENILIN 1; PSEN1

Posted in Stell Cell Genetics | Comments Off on OMIM Entry – * 104311 – PRESENILIN 1; PSEN1

Sanford stem cell trial crosses key threshold in offering …

Posted: March 8, 2019 at 6:42 am

Dec. 21, 2018

This paid piece is sponsored by South Dakota Biotech.

Sanford Research has hit a key milestone in its efforts to gain FDA approval for ground-breaking use of stem cells in orthopedics and is already pursuing new trials to broaden its efforts.

Early data has been released showing that the first patients who were part of a clinical trial using adipose-derived stem cells to treat rotator cuff tears had no harmful effects from the treatment.

We know all our patients were safe, but a significant amount of our patients also had pain relief and some function relief, said Tiffany Facile, Sanfords director of regenerative medicine.

That really contributes to the next phase.

The next step a phase two trial that is intended to show the treatments efficacy will include about 200 patients at 10 sites, starting in early 2019.

That study duration is about a year, Facile said.

Sanford has worked in partnership with a hospital in Munich, Germany, for years as the treatment was pioneered and offered to patients there. So while the results in the U.S. are welcomed, theyre not entirely surprising, she said.

We know from patients in Munich that there is relief. This is a confirmation of what we knew, but theres additional excitement because this could provide another treatment option for patients here, and it means a lot to me to be able to tell that to patients.

At the same time, Sanford is working through studies using adipose-derived stem cells to treat osteoarthritis in the wrist and in the back. Like the rotator cuff study, researchers have started by testing for safety and will follow with a trial for efficacy.

Sanford Health is well connected nationally and internationally in the regenerative medicine world, Facile said. I think because we have set the standard and maintained a great relationship with the FDA, we will continue to lead in this space.

Facile and David Pearce, executive vice president of innovation and research, will present in early 2019 at the World Stem Cell Summit in Miami, which features global leaders in the stem cell and regenerative medicine community.

Sanford is really trying to lead and be a good mentor for others to work with the FDA, Facile said. We can do it. We can do it the right way, but you just have to trust in the science and have science in the clinical application. We are sharing our story about how it can be done in the best way, and its an extreme honor.

Sanfords leadership in regenerative medicine is a huge asset in growing South Dakotas visibility within the bioscience industry, saidJoni Johnson, executive director of South Dakota Biotech.

This sort of activity in clinical trials is so exciting for our state, Johnson said. It broadens our relationships, leads to additional collaboration and helps continue to attract the sort of research talent that is lifting up our entire bioscience economy.

Sanfords success in pursuing stem cell clinical trials has bolstered its ability to recruit and collaborate, Facile agreed.

Its exciting. This is a competitive field, and were meeting with scientists nationally who are looking for clinical sites to conduct their studies, and Sanford is that place. Thats Sanford. So it gets me excited, and the fact that were following the FDA and bringing this treatment to patients in the right way is so important to take into consideration. Its the right thing for the patient.

See more here:
Sanford stem cell trial crosses key threshold in offering ...

Posted in South Dakota Stem Cells | Comments Off on Sanford stem cell trial crosses key threshold in offering …

Clinical Trial for Autism – cordbloodbank.com

Posted: March 8, 2019 at 6:41 am

Sarahs StoryTreating Autism with Stem Cells August 27, 2018 | Cord Blood Banking, Treatments Duke University Clinical Trial

In 2010, Anna and her husband decided to bank their son, Ryans, cord blood with New England Cord Blood Bank, Inc. (NECBB). Two years later, when their daughter Sarah was born, they opted to save her cord blood as well. Later, when Sarah was diagnosed with Autism, Anna thought about the possibility of using cord blood stem cells and began a quest to research medical advancements in stem cell therapies that could potentially benefit her daughters condition.

Anna joined Facebook Groups and scoured the internet looking for potential treatments for Sarah. After a year of researching options, Anna discovered a clinical trial run by Duke University. If accepted, Sarah could use her own stem cells to participate in the study. In June 2016, she was accepted into the trial.NECBB coordinated with the family and Duke University Hospital to oversee the logistics of transporting and delivery of the cryopreserved stem cells for Sarahs treatment. With high hopes, mother and daughter journeyed to Durham, North Carolina for the trial therapy.Sarahs first treatment was completed in February 2017. The family did not observe any changes in Sarah at that time. Her speech and language skills remained below grade level, her drawings were simple lines on paper and she remained socially awkward. Since the Duke University Hospital Study does not disclose clinical trial treatment information (placebo or stem cells), Anna speculates that the first treatment was, perhaps, a placebo. She does not know for sure. After Sarahs next session, dramatic improvements were noted. In less than a year, Sarahs language improved from two or three word sentences to 16 words and her scribbles on paper evolved into detailed images of flowers. In addition, her tantrums decreased dramatically and her social proficiency evaluation indicated that her skill set was off the charts.

Since the clinical trial at Duke University Hospital did not report the individual outcome to each participant, they only release a general report of the cumulative results, Sarahs success was evaluated independently. She is still on her Individual Education Plan (IEP) at pre-school, but her mother reports that everything is better. Its not a cure and there are still challenges, but there are improvements across the board. Anna notes that there are still lots of hurdles and developmental delays, yet their daughters progress has been exhilarating for the family. But Sarahs story isnt done yet. Her brother, Ryan, is a partial (50%) HLA match and therefore his cord blood stem cells can be used to extend her treatment. Anna has registered Sarah for an allogeneic (using stem cells from a donor, in this case Ryan) transplant this month as part of Dukes Expanded Access Protocol.

We need to stop throwing out these stem cells as medical waste, they are pure gold. I enrolled in this program at NECBB as an insurance policy for my kids. I hoped that I would never need these stem cells. By using a private bank, we had our own stem cells for our own use. Now, Im so glad we made this decision. NECBBs [staff] was knowledgeable and easy to work with, no stress at all. I read on various social media groups that parents discovered that their stem cell samples were contaminated after they applied for a trial. Other families couldnt get their medical reports or specimens released from their cord blood bank. These other banks put some childrens acceptance in the trial at risk. Anna said.

Anna remains hopeful that there will be a mesenchymal stem cell (MSCs) clinical trial for autism in the near future. MSCs are building block cells that not only can self replicate, but can also differentiate into many different cell types. With that trait they could one day repair or replace a wide variety of tissues, such as bone, cartilage, neural cells, muscle cells, and so on. MSCs can be found in umbilical cord tissue and dental pulp. Anna said she wishes she had stored Sarahs umbilical cord tissue when she preserved her cord blood. (NECBB offers the option of storing umbilical cord tissue, a source of MSCs). Additionally, NECBBs affiliate company, National Dental Pulp Laboratory, Inc. (NDPL) processes and stores MSCs collected from dental pulp or extracted teeth.

Anna added, Im excited about the potential of treatment. I hope that soon the FDA will open the floodgates so people can have access to this therapy. Its safe, so let people benefit from it. NECBB has shipped the siblings specimen to Duke University for Sarahs additional treatment. Anna is hopeful that Sarah will show continued development in combating the symptoms of Autism. She said the results to date have been astonishing; Sarah continues to flourish as a 5-1/2 year old girl. She is thriving in school and enjoying life with her friends.

NOTES: The names have been changed to protect the anonymity of the participants. This reviews the results of a Clinical Trial; the FDA has not approved stem cell transplants as a treatment for Autism. This should not be interpreted as a cure additionally, the story is not intended to imply there is a need for a cure.

View post:
Clinical Trial for Autism - cordbloodbank.com

Posted in North Carolina Stem Cells | Comments Off on Clinical Trial for Autism – cordbloodbank.com

Neuroscience Investigator Awards – New York Stem Cell …

Posted: March 8, 2019 at 6:41 am

The 2019 RFA is now closed.

NYSCF is soliciting applications from early career investigators for Innovator awards in neuroscience. The goal of this initiative is to foster truly bold, innovative scientists with the potential to transform the field of neuroscience. Applicants are encouraged in the fundamental areas of developmental, cellular, cognitive, and translational neuroscience, broadly interpreted. Applicants need not be working in areas related to stem cells.

The award provides $1.5M USD over 5 years and is open to researchers based at both national and international accredited academic and nonprofit research institutions.

To be eligible, candidates must:

*PLEASE NOTE ONLINE APPLICATION SUBMISSION PROCESS*All applications MUST be submitted through the online grant management system by February 20, 2019 at 5pm Eastern.

Register & Apply

Applicants must submit an Institutional Report Card for Gender Equality in order for the application to be considered complete. Details and FAQs can be found here.

Read more from the original source:
Neuroscience Investigator Awards - New York Stem Cell ...

Posted in New York Stem Cells | Comments Off on Neuroscience Investigator Awards – New York Stem Cell …

Faithfully Guided Health Center – Integrative Medicine …

Posted: March 8, 2019 at 6:41 am

Faithfully Guided Health Center takes an integrative and functional approach to primary care. Our priority is to spend the time necessary to uncover the root cause of your disease process vs. only treating the symptoms. Often times in medicine, practitioners provide symptom-management through medication, but fail to guide the patient to full healing and/or improved overall health and well-being.

Faithfully Guided Health Centers providers first spend time talking with and listening to you. We then perform an in-depth history, physical exam and diagnostic tests as needed. Our strategy is not to compartmentalize the body systems but identify how symptoms may be interrelated. We place a significant focus on gut and brain health as we believe this greatly influences the rest of the body.

Our treatment approach relies heavily on lifestyle medicine. We identify changes that can be made to improve nutrition, movement/exercise, restorative sleep/rest, environmental toxin exposure, and stress management. Along with the support of counselors and health coaches, we empower you to be involved with your own healing. Supplementation, medication, referrals to specialists and other treatment modalities will be recommended when needed.

Faithfully Guided Health Centers primary goal is to provide healing by connecting spirit, mind, and body through a collaborative approach to healthcare.

Helping the community achieve optimal health and abundant life is our vision! By providing faith-based lifestyle healthcare, we desire to be a part of the solution by improving the health outcomes of Marion County, from 46 out 62, and becoming one of the healthiest communities to live in Florida.

Faithfully Guided Health Center proudly offers free and on-going educational sessions for community members, groups and organizations throughout the Ocala, Florida and Marion County area.

Read this article:
Faithfully Guided Health Center - Integrative Medicine ...

Posted in Integrative Medicine | Comments Off on Faithfully Guided Health Center – Integrative Medicine …

Banking Stem Cells in Oklahoma City at Oral Surgery …

Posted: March 7, 2019 at 8:47 am

With recent advancements in medicine and research, we are just on the cusp of fully understanding the incredible potential of stem cells. Diseases that were initially thought to be untreatable may now be readdressed because of newly developed stem cell therapies. If banking stem cells could help you preserve your medical future or the future of someone you love, would you take advantage of the opportunity? Many people dont realize that our teeth house an abundance of healthy stem cells, which makes extracted teeth an appealing option for collection. In most cases, third molars are the only teeth that are still healthy when they are removed, making wisdom teeth removal the perfect opportunity for harvesting.

Were excited to announce that Oral Surgery Specialists of Oklahoma has partnered with Stemodontics. This partnership allows us to help eligible wisdom teeth patients store the stem cells from their dental pulp, which would otherwise be tossed out as medical waste. You can learn more about the process of stem cell banking by watching the helpful videos weve provided, visiting the Stemodontics website, or asking your doctor if stem cell banking is right for you.

The vast majority of patients have heard of stem cells but dont completely understand their nature or their viability. Stem cells naturally occur in the body, and they are responsible for the repair and restoration of tissues. Whereas specialized cells in your body can only regenerate and repair the same kind of cells muscle tissue cells can only duplicate into new muscle tissue cells, for example stem cells can repair any type of cell your body needs. They hold incredible potential for medical discovery because theyre not limited to a single cell type. Stem cells can heal and restore muscles, bones, skin, nerves, and much more.

As more advancements are made in medicine and research, doctors are discovering new and better methods for harvesting stem cells without pain and storing them in a controlled environment outside the body. These advances help the stem cells remain viable and allow them to be replicated for future use. Today, doctors and researchers are harnessing the power of stem cells and applying them in a manner that helps our bodies heal from diseases and injuries once thought untreatable.

Banking stem cells is a valuable opportunity for preserving your medical future, especially doing so while your stem cells are still healthy. When we are young, the stem cells in our bodies are healthy and in large quantity. However, every time stem cells duplicate, they lose a bit of value, meaning that as we get older, stem cells decline in both quantity and quality. If stem cells are banked early, such as during wisdom teeth removal, it maximizes their viability for future medical treatment.

At Oral Surgery Specialists of Oklahoma, we believe that everyone deserves the opportunity to preserve their medical future by banking stem cells. There are limited opportunities for safe and painless collection, which makes wisdom teeth extractions the most appealing option for harvesting.

Signing up with Stemodontics is easy! You can complete the enrollment process at our office before your surgical appointment. Your doctor will answer any questions you have about the process for collection and storage, and a member of our team will assist you in completing the online enrollment process. Once complete, the Stemodontics state-of-the-art laboratory sends a collection kit to our practice for your upcoming extraction. Once the tooth has been removed and properly stored, the Oral Surgery Specialists of Oklahoma team will ship it to the lab for immediate processing and storage. When youre ready to use your stem cell sample, all you need to do is contact Stemodontics. We will ship your sample to your designated healthcare provider.

Secure your medical future or the medical future of your loved ones by acting today! Click here to learn more about stem cell banking services through Stemodontics and enroll today.

Read the original post:
Banking Stem Cells in Oklahoma City at Oral Surgery ...

Posted in Oklahoma Stem Cells | Comments Off on Banking Stem Cells in Oklahoma City at Oral Surgery …

Can Stem Cell Therapy Save Your Knees? – SS&RM

Posted: March 7, 2019 at 8:46 am

Similar to spackle filling in the cracks, a new procedure taps into your bodys reserves to repair joint injuries with your own cells. So far so good.

Krista Crabtree, Contributor, SKI Magazine Oct 10, 2017

For near two decades, Tim Petrick skied with constant pain in his right knee. As the former President and CEO of K2 Sports and the current COO at Silverton Mountain in Colorado, hes had the fortune to ski some of the worlds most majestic mountains, and has probably made several million, mostly satisfying, turns.

But in 2000, one of a skiers worst fears struck while Petrick was heli skiing in Alaska. I tumbled down a couloir following (the late) Doug Coombs in deep powder and blew my ACL out, says Petrick. I also lost parts of my medial and lateral meniscus from going end over end. After surgery to repair his ACL, his knee deteriorated over the next decade and he was prescribed an unloader knee brace, which mitigated the pain just enough so he could ski. I wore that brace religiously because if I didnt wear it, my knee would ache like crazy, he says.

Petrick knew he was a classic candidate for total knee replacement surgery, but that seemed like a daunting decision to him. After years of being a hard-charging athlete, it also felt a bit like a defeat, a surrender of sorts on the battlefield of your body.

His doctor, Mark D. Wagner, MD, of Seattle Sports & Regenerative Medicine, recommended an alternative to the invasive joint replacement surgery. Wagner, an avid skier himself, had recently begun performing a procedure called Stem Cell Therapy. The procedure uses the patients own stem cells mixed with a sample of bone marrow and adipose tissue, which is spun in a centrifuge and injected into the damaged joint in what Wagner likens to spackle filling in the cracks. You can also think of the stem cells as seeds you put on the bare spots on your lawn, says Wagner. Your platelets are the fertilizer, promoting growth. The stem cells sense the environment, go into the joint, and lay down new cartilage.

READ FULL ARTICLE

Here is the original post:
Can Stem Cell Therapy Save Your Knees? - SS&RM

Posted in Alaska Stem Cells | Comments Off on Can Stem Cell Therapy Save Your Knees? – SS&RM

Regenerative Medicine in Patient Care – Center for …

Posted: March 7, 2019 at 8:45 am

Regenerative medicine-based services are available to patients, including a consult service and one of the country's largest transplant centers.

Patients at Mayo Clinic are becoming increasingly interested in whether there are any regenerative medicine applications suitable for their conditions. To meet this interest, the Regenerative Medicine Consult Service was launched within the Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration in 2011.

Teams composed of bone specialists, biologists and engineers at Mayo Clinic are investigating the potential of simple hip decompression, a new regenerative technique, for patients with early-stage osteonecrosis of the hip.

Transplant medicine laid much of the groundwork for the field of regenerative medicine. Today, transplantation (replacement) is one of the three approaches being studied and applied by the Center for Regenerative Medicine to restore tissue and organ function.

Mayo Clinic has the largest and most experienced transplant practice in the United States. In total, Mayo's campuses in Arizona, Florida and Minnesota perform more than 1,500 solid organ and bone marrow transplants each year. Staff members skilled in more than a dozen specialties work together to ensure quality care and successful recovery.

.

Read this article:
Regenerative Medicine in Patient Care - Center for ...

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine in Patient Care – Center for …

Gene expression in stem cells | Data Nuggets

Posted: March 7, 2019 at 8:45 am

Adam working in the lab at Colorado State University.

Theactivitiesare as follows:

Every cell in your body contains the same DNA. How is it that genetically identical skin, brain, and muscle cells can look very different and perform very different functions from each other? Cells differentiate, or become different from one another, by turning certain genes on and off. This process is called gene expression. For example, when you spend time in the sun your skin cells turn on the gene for pigment, which protects your cells from bright sunlight. In the winter when there is less sunlight, your cells turn off this gene. This process your body uses to turn genes on and off is the same one it uses to develop from one cell into the many different cell types that make up your body. Stem cells have the ability to turn into any other type of cell in the body, an ability known as pluripotency. Your body retains some stem cells for your entire life.

Some genes are only turned on in specific types of cells because they have specialized jobs for those cell types, like muscle or brain cells. Other genes are more like managers, controlling which genes are turned on and off. The activity of these manager genes maybe more common in stem cells because they could control which type of cell the stem cell will become. In recent years, scientists discovered they could reprogram specialized cells back into non-specialized stem cells, simply by turning on several manager genes. They call these reprogrammed cells induced pluripotent, or iPS.

Adam working under the hood, reprogramming specialized cells into induced pluripotent stem cells for his experiments.

Adam was working as a biologist in Colorado when he learned that many cool medical advances in regenerative and personalized medicine will happen when we figure out which genes are turned on, and which are turned off, in pluripotent stem cells. In his research, Adam wanted to look at gene expression for two genetically identical cell lines, those that have specialized and those that have been reprogrammed to be iPS stem cells. He was interested to see which genes are expressed by both types of cells and which genes are only expressed in one type of cell.

He decided to work with fibroblast cells because they are easy to grow in the lab. Fibroblasts cells are mainly responsible for production and maintenance of the extracellular matrix (including joints, ligaments, tendons and connective tissues), which is critical in holding the bodys tissues together. From reading the work of other scientists, Adam learned how to transform fibroblast cells into iPS stem cells. This knowledge lead him to two genetically identical types of cells (1) specialized fibroblast cells and (2) unspecialized iPS cells. When fibroblast cells are transformed into unspecialized iPS cells, their function changes and they become responsible for wound healing and generating new tissues, acting like a reserve set of cells. Because fibroblast and iPS cells perform very different functions, Adam thinks it is likely that each cell line will expresses genes that are specific to its individual function.

Adam looked at expression in 10 different genes that are thought to have important functions for fibroblast or iPS cells. Adam measured the expression for each gene by looking at RNA abundance of each gene in the different cell types. RNA is the intermediate between DNA (the genetic blueprint) and protein (the functional worker of the cell). Adam chose to look at RNA, because it is often representative of how much protein is present in a cell, which is very difficult to measure directly. Adam analyzed three replicates for each cell type. He replicated in order to get a more accurate representation for each cell type. This is important in case the samples were in slightly different conditions, like warmer or cooler temperatures, which could alter gene expression. This experiment allowed Adam to figure out which genes are turned on in iPS cells, allowing him to better understand how stem cells work.

iPS cells display different gene expression and physical appearance than HFF cells: Figures A and B are low magnification images of two different iPS cell colonies. iPS cells are usually small, round, and like to grow in circular-like colonies. Figures C is a low magnification image of HFF cells. HFF cells tend to appear long and slender almost like trees. Generally, HFF cells like to grow near each other, but not in colonies. Figure D is a higher magnification image of the black box in figure C, showing a group of HFF cells growing in close proximity with each other.

Featured scientist: Adam Heck from Colorado State University. Written withSandra Weeks from the Poudre Valley School District.

FleschKincaid Reading Grade Level= 10.6

To learn more about the researching being done in Adams lab, click here.

The gene expression data found in this activity wasgathered from the following paper citation and link below:

Read more here:
Gene expression in stem cells | Data Nuggets

Posted in Colorado Stem Cells | Comments Off on Gene expression in stem cells | Data Nuggets

Page 1,389«..1020..1,3881,3891,3901,391..1,4001,410..»